Previous 10 | Next 10 |
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into a clinical trial collaboration and supply agreement with Bayer AG for Celcuity ...
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology ...
2023-08-10 20:15:20 ET Celcuity Inc. (CELC) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Robert Uhl – ICR Westwicke Brian Sullivan – Chief Executive Officer and Co-Founder Vicky Hahne – Chief Financial Offi...
2023-08-10 16:31:14 ET Celcuity press release ( NASDAQ: CELC ): Q2 GAAP EPS of -$0.66 misses by $0.06 . At June 30, 2023, Celcuity reported cash, cash equivalents and short-term investments of $146.2 million. For further details see: Celcuity GAAP EPS of -$0....
Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countries Presented updated results from Phase 1b study of gedatolisib in treatment-naïve advanced breast cancer at the ESMO Breast Cancer Annual Congress Median progression free survival (...
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2023 after the stock market close on Thu...
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in on...
MINNEAPOLIS, MN / ACCESSWIRE / June 20, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, is set to join the Russell 2000 ® and 3000 ® Indexes at the conclusion of the 2023 Russell indexes annual reco...
2023-05-15 22:47:13 ET Celcuity Inc. (CELC) Q1 2023 Earnings Conference Call May 15, 2023 04:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Conference Call Participants Maury Raycroft...
2023-05-15 16:19:01 ET Celcuity press release ( NASDAQ: CELC ): Q1 GAAP EPS of -$0.55 misses by $0.03 . At March 31, 2023, Celcuity had cash, cash equivalents and short-term investments of $157.5 million. For further details see: Celcuity GAAP EPS of -$0.55 m...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...